Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$24.84
+1.4%
$23.61
$14.75
$26.16
$2.99B0.71.11 million shs937,199 shs
Merus stock logo
MRUS
Merus
$50.80
-7.9%
$42.93
$33.19
$61.28
$3.82B0.94741,469 shs2.72 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$29.46
-1.0%
$33.41
$26.74
$46.00
$2.26B1.21525,847 shs1.06 million shs
Xencor, Inc. stock logo
XNCR
Xencor
$7.75
+2.4%
$9.45
$7.16
$27.24
$551.58M0.99657,047 shs1.49 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
+1.43%+0.65%+5.93%+20.70%+56.52%
Merus stock logo
MRUS
Merus
-7.87%+15.43%+16.59%+11.57%-15.32%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-0.97%-6.27%-21.69%-24.65%-23.22%
Xencor, Inc. stock logo
XNCR
Xencor
+2.38%-4.79%-26.26%-46.11%-67.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
4.7222 of 5 stars
3.61.00.03.94.33.32.5
Merus stock logo
MRUS
Merus
3.05 of 5 stars
4.63.00.00.02.71.70.0
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.4887 of 5 stars
4.54.00.00.03.61.70.0
Xencor, Inc. stock logo
XNCR
Xencor
3.9356 of 5 stars
3.41.00.03.93.70.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.13
Buy$32.2929.97% Upside
Merus stock logo
MRUS
Merus
3.13
Buy$86.0069.29% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$54.8286.08% Upside
Xencor, Inc. stock logo
XNCR
Xencor
2.89
Moderate Buy$29.50280.65% Upside

Current Analyst Ratings Breakdown

Latest XNCR, MRUS, CPRX, and XENE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
Merus stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/19/2025
Merus stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/14/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00 ➝ $53.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $55.00
5/8/2025
Merus stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
5/8/2025
Xencor, Inc. stock logo
XNCR
Xencor
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.00
5/7/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$534.65M5.67$2.32 per share10.72$3.30 per share7.53
Merus stock logo
MRUS
Merus
$54.73M64.24N/AN/A$6.17 per share8.23
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M301.41N/AN/A$14.18 per share2.08
Xencor, Inc. stock logo
XNCR
Xencor
$127.23M4.34N/AN/A$10.99 per share0.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$71.41M$1.5721.0511.663.3131.01%40.79%34.87%8/6/2025 (Estimated)
Merus stock logo
MRUS
Merus
-$154.94M-$4.08N/AN/AN/A-680.61%-38.89%-31.16%7/30/2025 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$182.39M-$3.23N/AN/AN/AN/A-24.69%-23.68%8/14/2025 (Estimated)
Xencor, Inc. stock logo
XNCR
Xencor
-$126.09M-$3.06N/AN/AN/A-232.77%-30.92%-21.74%8/4/2025 (Estimated)

Latest XNCR, MRUS, CPRX, and XENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Merus stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/12/2025Q1 2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million
5/8/2025Q1 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Merus stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
5.11
4.92
Merus stock logo
MRUS
Merus
N/A
8.32
8.32
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
22.21
22.21
Xencor, Inc. stock logo
XNCR
Xencor
0.01
6.23
6.23

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Merus stock logo
MRUS
Merus
96.14%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%
Xencor, Inc. stock logo
XNCR
Xencor
N/A

Insider Ownership

CompanyInsider Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Merus stock logo
MRUS
Merus
4.57%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
5.52%
Xencor, Inc. stock logo
XNCR
Xencor
4.76%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80121.98 million106.15 millionOptionable
Merus stock logo
MRUS
Merus
3769.21 million65.34 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21076.73 million72.03 millionOptionable
Xencor, Inc. stock logo
XNCR
Xencor
28071.17 million66.32 millionOptionable

Recent News About These Companies

Xencor Reports First Quarter 2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$24.84 +0.35 (+1.43%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$24.76 -0.09 (-0.34%)
As of 05/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Merus stock logo

Merus NASDAQ:MRUS

$50.80 -4.34 (-7.87%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$51.20 +0.40 (+0.79%)
As of 05/27/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$29.46 -0.29 (-0.97%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$29.92 +0.46 (+1.56%)
As of 05/27/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xencor stock logo

Xencor NASDAQ:XNCR

$7.75 +0.18 (+2.38%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$7.76 +0.00 (+0.06%)
As of 05/27/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.